Spotlight on rare NMOSD: Chord launches with $16m Series A round
Omega Funds has backed Chord Therapeutics with $16m Series A funding. This money will be used to advance CRD1, Chord’s…
By
Venture Capital
Latest in
Venture Capital
Targeting PP2A to tackle cancers: Rappta closes €9m Series A round
PP2A has long been recognised as a promising target in oncology, but it has remained elusive to scientists. Helsinki-based Rappta…
By
Targeting the tumour stroma: Phenomic AI launches with $6m seed financing
Phenomic AI has secured $6m in seed funding, which it plans to use to advance its two lead candidates into…
By
Tackling fibrosis: Galecto raises $64m in equity financing
Eir Ventures and Soleus Capital have co-led a $64m equity financing into Galecto and its novel approach to tackling fibrosis.…
By
Next-gen gene editing: Graphite Bio launches with $45m funding
After raising $45m in a successful Series A round, Graphite has launched with its next-generation gene editing platform. How does…
By
Powering biologics development with spirulina: Lumen closes $16m Series B
Lumen Bioscience has raised $16m in a Series B financing round to support its clinical programmes in prevalent but overlooked…
By
Advancing AAV gene therapy: Forge closes $40m Series A
Forge has completed a $40m Series A round, led by the PXV Fund, which will be enable the company to…
By
Linking cancer and fibrosis: iOnctura raises €20.1m in a Series A round
Swiss biotech iOnctura has closed a Series A round with €20.1m raised. The round was supported by existing investors –…
By